ACADIA PHARMACEUTICALS INC.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: Acadia Pharmaceuticals AB based in Malmo, Sweden and Acadia Pharmaceuticals A/S based in Denmark. The Company is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neuro... logical and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinson's disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimer's disease psychosis, for which it is initiating a Phase II feasibility study.
ACADIA PHARMACEUTICALS INC.
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1993-07-16
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.acadia-pharm.com
Total Employee:
501+
Status:
Active
Contact:
(858) 558-2871
Email Addresses:
[email protected]
Total Funding:
811.73 M USD
Technology used in webpage:
SPF Google Tag Manager Domain Not Resolving Global Site Tag Mobile Non Scaleable Content Euro IPv6 Google Maps Google Maps API Cloudflare Hosting
Similar Organizations
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-08-25 | CerSci Therapeutics | CerSci Therapeutics acquired by Acadia Pharmaceuticals Inc. | 52.5 M USD |
Investors List
National Institute of Neurological Disorders and Stroke
National Institute of Neurological Disorders and Stroke investment in Grant - Acadia Pharmaceuticals Inc.
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - Acadia Pharmaceuticals Inc.
Venrock
Venrock investment in Post-IPO Equity - Acadia Pharmaceuticals Inc.
Nomura International
Nomura International investment in Post-IPO Equity - Acadia Pharmaceuticals Inc.
Oxford Bioscience Partners
Oxford Bioscience Partners investment in Post-IPO Equity - Acadia Pharmaceuticals Inc.
Oxford Bioscience Partners
Oxford Bioscience Partners investment in Post-IPO Equity - Acadia Pharmaceuticals Inc.
ABN AMRO Fund
ABN AMRO Fund investment in Series F - Acadia Pharmaceuticals Inc.
OrbiMed
OrbiMed investment in Series F - Acadia Pharmaceuticals Inc.
LD Pensions
LD Pensions investment in Series F - Acadia Pharmaceuticals Inc.
Federated Investors
Federated Investors investment in Series F - Acadia Pharmaceuticals Inc.
Key Employee Changes
Official Site Inspections
http://www.acadia-pharm.com Semrush global rank: 3.31 M Semrush visits lastest month: 4.9 K
Unable to get host informations!!!
More informations about "Acadia Pharmaceuticals Inc."
About Acadia Pharmaceuticals
This page is intended as an educational resource for U.S. healthcare professionals. The list of Acadia-sponsored publications below may contain information about doses, uses, formulations and populations different from …See details»
Acadia Pharmaceuticals Canada: Breakthroughs in …
Oct 16, 2024 At Acadia Canada, we are committed to developing therapies in areas with high unmet needs, elevating life to ensure a brighter future for all. ... [email protected] Media Inquiries …See details»
Acadia Pharmaceuticals - Wikipedia
Acadia started in 1993 as Receptor Technologies, based in Winooski, Vermont. In 1997, the company relocated all operations and management from Vermont to San Diego, California as a strategic move to garner partnerships with other biotechnology companies. However, the company also had an office in Denmark, in which it received a crucial part of its early investments from BankInvest, under managing director Florian Schönharting, Kommunernes Pensionsforsikr…See details»
Acadia Pharmaceuticals Inc. - Crunchbase Company …
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned …See details»
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia ...
Sep 23, 2024 Owen Adams was formerly on the board of directors and chair of the compensation committee for Optinose PLC, a public specialty pharmaceutical company, and …See details»
Acadia Pharmaceuticals - The Org
Acadia is trailblazing breakthroughs in neuroscience to elevate life. They are at the forefront of healthcare, fighting for breakthroughs in our science, their therapies and the way we work, but …See details»
Acadia Pharmaceuticals Inc. Information - RocketReach
Acadia strongly recommends individuals, who receive email solicitations, to carefully verify the authenticity of the correspondence before responding. Never provide personal information or …See details»
ACADIA Pharmaceuticals Inc. (ACAD) Company Profile & Overview …
May 27, 2004 The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was …See details»
Acadia Pharmaceuticals Inc. - LinkedIn
12830 El Camino Real Suite 400 San Diego, California 92130-3331, USSee details»
ACADIA - Overview, News & Similar companies | ZoomInfo.com
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it …See details»
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia ...
Sep 23, 2024 Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani (858) 261-2872 [email protected]. Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818) …See details»
Acadia Pharmaceuticals Announces Exclusive License Agreement …
Nov 26, 2024 Acadia Pharmaceuticals Inc. Al Kildani (858) 261-2872 [email protected]. Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818) 395-3043 media@acadia …See details»
Patient Resources - Acadia Pharmaceuticals
We are engaged with organizations supporting Acadia’s full portfolio. Below are examples of some of the organizations we work closely with: American Parkinson Disease Association …See details»
Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice ...
Acadia Pharmaceuticals Inc. Stephanie Fagan (858) 212-0534 [email protected]. Investor Contact: Acadia Pharmaceuticals Inc. Mark Johnson, CFA (858) 261-2771 ir@acadia …See details»
Acadia Pharmaceuticals to Participate at Upcoming Investor …
Nov 21, 2024 SAN DIEGO--(BUSINESS WIRE)--Nov. 21, 2024-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor …See details»
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia ...
Sep 23, 2024 Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818) 395-3043 [email protected] Contacts Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani …See details»
Our History | Acadia Pharmaceuticals
Acadia initiates Phase 3 CLARITY program with pimavanserin as adjunctive treatment for major depressive disorder. ‡ Acadia presents positive top-line results from pivotal Phase 3 …See details»
Acadia Pharmaceuticals Reports Third Quarter 2024 ... - Morningstar
Nov 6, 2024 Acadia will host a conference call to discuss the third quarter 2024 results today, Wednesday, November 6, 2024 at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be …See details»
Acadia Pharmaceuticals Announces Exclusive License Agreement …
Nov 26, 2024 Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani (858) 261-2872 [email protected]. Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818) …See details»
Acadia Pharmaceuticals Announces Exclusive License Agreement …
SAN DIEGO, November 26, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: …See details»